Molecular structure of Chidamide, CAS Number: 743420-02-2
Chidamide (CAS 743420-02-2)
Alternate Names:
N-(2-amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)- 2-propen-1-yl]amino]methyl]-benzamide
Application:
Chidamide is an HDAC inhibitor
CAS Number:
743420-02-2
Molecular Weight:
390.41
Molecular Formula:
C22H19FN4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Chidamide is a histone deacetylase (HDAC) inhibitor that functions by binding to the active site of HDAC enzymes, thereby preventing the deacetylation of histone proteins. This inhibition leads to the accumulation of acetylated histones, resulting in a more relaxed chromatin structure and increased accessibility of DNA to transcription factors and other regulatory proteins. As a result, chidamide can modulate gene expression and regulate various cellular processes, including cell cycle progression, apoptosis, and differentiation. By targeting HDAC enzymes, chidamide plays a role in epigenetic regulation and may influence the transcriptional activity of specific genes. Chidamide′s mechanism of action involves its interaction with the catalytic domain of HDAC enzymes.
Chidamide (CAS 743420-02-2) References
- Chidamide in the treatment of peripheral T-cell lymphoma. | Chan, TS., et al. 2017. Onco Targets Ther. 10: 347-352. PMID: 28138258
- Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. | Shi, Y., et al. 2017. J Hematol Oncol. 10: 69. PMID: 28298231
- Chidamide tablets: HDAC inhibition to treat lymphoma. | Xu, Y., et al. 2017. Drugs Today (Barc). 53: 167-176. PMID: 28447074
- Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. | Que, Y., et al. 2021. J Immunother Cancer. 9: PMID: 33637599
- Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway. | Zhang, H., et al. 2021. Mol Med Rep. 23: PMID: 33649847
- Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review. | Li, L., et al. 2021. Int J Immunopathol Pharmacol. 35: 20587384211009342. PMID: 33845613
- Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas. | Huang, X., et al. 2021. J Oncol. 2021: 4936207. PMID: 34194495
- Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma. | Xue, K., et al. 2021. Cell Death Dis. 12: 900. PMID: 34599153
- A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. | Liu, W., et al. 2021. Front Oncol. 11: 750323. PMID: 34804937
- Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells. | Zhao, H., et al. 2022. Exp Hematol Oncol. 11: 29. PMID: 35581670
- Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression. | Cao, L., et al. 2022. Clin Epigenetics. 14: 84. PMID: 35799216
- Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. | Cao, HY., et al. 2022. Hematol Oncol.. PMID: 36251458
- The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review. | Ridwansyah, H., et al. 2023. Biomol Biomed.. PMID: 37004241
Inhibitor of:
A530032D15Rik, ANKRD26, BAGE4, Btnl1, c-Myb, C14orf43, C6orf32, CECR2, CHRAC17, Dpy30, Elongin C, EZI, FAM120AOS, GAGE, GAGE12G, GATAD (GATA zinc finger domain containing), GATAD2A, GM-CSFRβ, H2-M10.1, H2BFWT, H3.Y histone 1, HAT1, HDA1, HDA4, HDA5, HDA7, HDAC, HDAC1, Hils1, Histone B, Histone cluster 1 H2A, Histone cluster 1 H2AG, Histone cluster 1 H2B, Histone cluster 1 H3B, Histone cluster 1 H4, Histone cluster 1 H4H, Histone cluster 1 H4L, Histone cluster 2 H2AA3, Histone cluster 2 H2AC, Histone cluster 2 H3A, Histone cluster 2 H3C1, Histone cluster 2 H4, JAZF1, KRT222P, KTELC1, Lacrein, LIN-35, LIR-6, LMO1, LOC665622, LOH11CR2A, LRIG3, MAGE-A9, MAGE-A9B, MAGE-B1, MAGE-B18, MAGE-B3, MAGE-E2, Mammaglobin A, MIER1, Morc3, MORF4L2, MRG15, mSin3A9, Mxi 1, NKAP, NWD1, p150, PAGE-2, PATE2, PCDHB13, PHF12, PLZF, PRDM15, PTPRH, RFXDC2, RP23-480B19.10, RUNX3, SAP 30L, SMRT/SMRTe, SPIN2, STAMP2, TAF1L, TMEM59, TPSD1, TSPY9, TSSC4, ZBRK1, ZBTB (Zinc finger BTB domain containing), ZCWPW1, ZCWPW2, and ZMYM6NB.Activator of:
2900008C10Rik, ATF-7IP, BRD3, Histone cluster 1 H2B, Histone cluster 1 H2BH, Histone cluster 1 H3F, Histone cluster 1 H3H, Histone cluster 1 H4I, Histone cluster 3 H3, Mxi 1, SETBP1, and SWI/SNF-B.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chidamide, 1 mg | sc-364462 | 1 mg | $62.00 | |||
Chidamide, 5 mg | sc-364462A | 5 mg | $250.00 | |||
Chidamide, 25 mg | sc-364462B | 25 mg | $1196.00 |